Warfarin-is a medication that is used as an anticoagulant.

Warfarin-sold under the brand name Coumadin among others, is a medication that is used as an anticoagulant.

Warfarin-is a medication that is used as an anticoagulant.

Warfarin; Coumadin; Coumafene; Prothromadin

Uniwarfin, Sofarin, Warf

4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one

Oral absorption with 99% bound to protein (Albumin). Hepatic metabolism, excreted via urine.

It is a racemic mixture of two active isomers, used in the prevention and treatment of thromboembolic disease including thromboembolism, pulmonary embolism and venous thrombosis it is also used to prevent ischemic stroke in patients with atrial fibrillation (AF).

5 mg daily

For the treatment of pulmonary embolism, retinal vascular occlusion, cardiomyopathy, flutter, atrial fibrillation, transient cerebral ischaemia, cerebral embolism, arterial embolism and thrombosis.

Hypersensitivity, rash, alopecia, diarrhea, drop in haematocrit, Haemorrhage, purple toes syndrome, skin necrosis, jaundice, nausea, vomiting, hepatic dysfunction, pancreatitis, increased LFT.

• Avoid major changes in dietary intake of Vitamin K (green vegetables eg broccoli, spinach). Increased anticoagulant effects with chamomile, cranberry, gingko biloba, alfalfa, black cohosh, dong quai, celery, clove, capsicum, fenugreek, omega 3 triglycerides and ginger.
• Reduced anticoagulant effect with St John's wort, Panax ginseng, coenzyme Q10, mistletoe.

• Contraindicated in pregnancy.
• Hypersensitivity
•  Haemorrhagic tendencies or blood dyscrasia; recent surgery; peptic ulcer; severe hypertension; bacterial endocarditis; psychosis; cerebrovascular disorders; senility; pericarditis; aneurysms; eclampsia; pericardial effusion; pre-eclampsia; threatened abortion; alcoholism; severe renal and hepatic impairment

Protect from light.  Store at 15-30°C (59-80°F). 

Molecular weight

308.3279

Molecular formula

C19H16O4

CAS number

81-81-2

Precautions

• Heparin induced thrombocytopenia, DVT, infectious disease, disturbances of intestinal flora, surgery or trauma, indwelling catheters, hypertension, Vitamin K, Vitamin C, protein S or C deficiency.
• Discontinue therapy if necrosis develops.
• Elderly, alcoholics, lactation
• Periodic determination of PT/INR. Patient to report any signs of bleeding, symptoms of blood clot and avoid activities or sports that can cause injuries.
• Purple toes syndrome may occur between 3-10 wk after start of therapy.
• An INR>4 represents higher risk of bleeding while INR <2 generally represents insufficient anticoagulation.